Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.33 |
| ▸ | MDM4 | O15151 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6692830 | 0.82 | LMNA (0.35) | RAB9ALMNASMN1; SMN2GAAKDM4E | |
| SCHEMBL6316794 | 0.81 | LMNA (0.39) | RAB9ALMNASMN1; SMN2GAAMDM2 | |
| SCHEMBL6320492 | 0.78 | LMNA (0.40) | LMNASMN1; SMN2GAAKDM4EHRH3 | |
| SCHEMBL6689841 | 0.78 | ALOX5 (0.34) | RAB9ALMNASMN1; SMN2NR1H2NR1H3 | |
| SCHEMBL6316848 | 0.77 | LMNA (0.41) | LMNASMN1; SMN2GAAKDM4EHRH3 | |
| SCHEMBL6324178 | 0.76 | AVPR1B (0.39) | RAB9ALMNASMN1; SMN2GAA | |
| SCHEMBL6689299 | 0.75 | LMNA (0.35) | RAB9ALMNASMN1; SMN2GAAKDM4E | |
| SCHEMBL6315745 | 0.75 | GAA (0.40) | LMNASMN1; SMN2GAAALOX5 | |
| SCHEMBL6695220 | 0.73 | GAA (0.39) | RAB9ALMNASMN1; SMN2GAA | |
| SCHEMBL6316797 | 0.72 | KMT2A (0.38) | RAB9ALMNASMN1; SMN2GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075348-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075348-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | ACKR3, CCR5, CXCR4 | RAB9A 2442/4885LMNA 4803/4885SMN1; SMN2 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.